We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Immunomedic’s Trodelvy (sacituzumab govitecan-hziy) earned accelerated approval for treatment of adults with triple-negative breast cancer that has metastasized. Read More